
Nurtec ODT is owned by Pfizer Inc. (NYSE: PFE), a publicly traded American pharmaceutical company headquartered in New York City. Pfizer obtained Nurtec through its October 2022 acquisition of Biohaven Pharmaceutical for approximately $11.6 billion. Nurtec ODT (rimegepant) is a CGRP receptor antagonist first FDA approved in February 2020 for acute migraine treatment.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Nurtec ODT | Pfizer Inc. | Product line |
Rimegepant originated in Bristol-Myers Squibb's research programs on calcitonin gene-related peptide antagonists, a mechanism identified decades ago as central to migraine pathophysiology. BMS deprioritized the compound, and Biohaven, a Connecticut-based biotech founded by Vladimir Coric and colleagues in 2013, licensed it along with the broader CGRP portfolio and pushed it into late-stage development.
Biohaven's trials demonstrated that rimegepant could treat acute migraine attacks and, taken every other day, also prevent them, a dual indication unusual among migraine therapies. The FDA approved Nurtec ODT for acute migraine treatment in February 2020, a launch complicated by the arrival of the COVID-19 pandemic within weeks of approval, which forced Biohaven to build commercial traction largely through digital marketing and telehealth when physician detailing was restricted.
The preventive indication was added in May 2021, making Nurtec the only CGRP oral agent approved for both acute treatment and prevention. The drug's orally disintegrating tablet format, designed for patients who cannot swallow during attacks, differentiated it from competitors including AbbVie's Ubrelvy.
Pfizer acquired Biohaven for approximately $11.6 billion in October 2022, a deal driven primarily by the Nurtec franchise and the CGRP pipeline. The non-CGRP Biohaven assets were spun out to shareholders as a separate company, Biohaven Ltd., retaining the neuroscience pipeline while Pfizer took the migraine business. Under Pfizer, Nurtec has been integrated into a commercial infrastructure vastly larger than Biohaven's, expanding its prescriber reach and international filings.
What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.
Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.
Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.
Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.
How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.
Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.
What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.
Nurtec's public record is relatively clean. The drug's main reported adverse events include nausea and hypersensitivity reactions labeled in the prescribing information, with post-marketing surveillance ongoing as for all newer agents.
Controversy at the corporate level touched the Biohaven acquisition indirectly: Biohaven's founders and its scientific claims around the broader pipeline attracted short-seller skepticism during its independent years, questions that became Pfizer's to absorb when it bought the CGRP business. The spin-out structure, which left the non-migraine assets outside Pfizer, was itself a debated transaction structure in biotech coverage.
No product recall has occurred. Pricing follows the brand-name pharmaceutical norm and has drawn the standard criticism applied to new migraine therapies costing hundreds of dollars per dose pack before insurance.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Novartis | Switzerland | 1997 | Mass market | Global | All Genders |
Market Positioning: Nurtec ODT competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Pfizer Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
Boots is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
Duane Reade is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
Pharmacy Direct is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
Retavase is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Walgreens is the largest U.S. pharmacy retail brand, operating roughly 8,000 stores. It went private in August 2025 under Sycamore Partners as a standalone company.
Walgreens is privately owned, unlike Nurtec ODT which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.